The Seattle Heart Failure Model
Top Cited Papers
Open Access
- 21 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (11), 1424-1433
- https://doi.org/10.1161/circulationaha.105.584102
Abstract
Background— Heart failure has an annual mortality rate ranging from 5% to 75%. The purpose of the study was to develop and validate a multivariate risk model to predict 1-, 2-, and 3-year survival in heart failure patients with the use of easily obtainable characteristics relating to clinical status, therapy (pharmacological as well as devices), and laboratory parameters.Keywords
This publication has 35 references indexed in Scilit:
- Mortality Reduction by Implantable Cardioverter-Defibrillators in High-Risk Patients With Heart Failure, Ischemic Heart Disease, and New-Onset Ventricular Arrhythmia: An Effectiveness StudyJournal of the American College of Cardiology, 2005
- Usefulness of Relative Lymphocyte Count as an Independent Predictor of Death/Urgent Transplant in Heart FailureThe American Journal of Cardiology, 2005
- Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failureThe American Journal of Cardiology, 2005
- Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving β-blockersThe Journal of Heart and Lung Transplantation, 2004
- Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failureThe American Journal of Cardiology, 2004
- Statin therapy is associated with lower mortality among patients with severe heart failureThe American Journal of Cardiology, 2004
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity Commentary: Time for a controlled trial?BMJ, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999